Evaluation of Glucose Control in Patients With Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

125 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-02-06

Study Completion Date

2018-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, multicenter, open-labeled, parallel, three group pilot study to evaluate the impact of a diabetes-specific nutritional shake on glucose control.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Nutritional Products in Subjects With Type 2 Diabetes

NCT02923960

Diabetes

COMPLETED NA

Glucose/Insulin Responses:Subjects With Type 2 Diabetes Consuming Diabetes-Specific vs Standard Nutritional Formulas

NCT00540488

Diabetes Mellitus Type 2

COMPLETED PHASE3

Effects of Nutritional Products on Blood Glucose in Subjects With Type 2 Diabetes

NCT00753181

Diabetes Mellitus, Type 2

COMPLETED PHASE3

Comparison of Nutritional Products for People With Type 2 Diabetes

NCT00520065

Type 2 Diabetes Mellitus

COMPLETED PHASE2

An Exploratory Investigation to Assess Changes in Quality of Life for Individuals With Type 2 Diabetes After Taking a Meal-replacement Shake.

NCT05129735

Diabetes Mellitus, Type 2

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glycemic Control

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Usual Diet Group

Instructed to continue to maintain a diet pattern of three main meals (breakfast, lunch and dinner) with two daily snacks including a usual snack (of their own choosing) mid-morning and a usual snack (of their own choosing) mid-afternoon.

Group Type OTHER

Usual Diet Group

Intervention Type OTHER

three main meals and two snacks

Group 1 Nutritional Shake

Instructed to consume one nutrition shake instead of their usual breakfast and consume the second nutrition shake for their mid-afternoon snack.

Group Type EXPERIMENTAL

Group 1 Nutritional Shake

Intervention Type OTHER

2 servings per day

Group 2 Nutritional Shake

Instructed to consume one Study Shake instead of their usual breakfast and the second Study Shake for the second snack before bed-time.

Group Type EXPERIMENTAL

Group 2 Nutritional Shake

Intervention Type OTHER

2 servings per day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Usual Diet Group

three main meals and two snacks

Intervention Type OTHER

Group 1 Nutritional Shake

2 servings per day

Intervention Type OTHER

Group 2 Nutritional Shake

2 servings per day

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type 2 diabetes as evidenced by the use of metformin, thiazolidinones, or sulfonylureas, alone or in combination, with constant dose for a least 2 months prior to Screening and is able to maintain medication dose throughout the duration of the study
* A1C ≥ 7.0% and ≤ 10.0%
* Follows a consistent eating pattern of 3 main meals with snacks
* BMI ≥ 25.0 and ≤ 40.0 kg/m2
* Stable body weight for the past 2 months prior to Screening Visit
* If on thyroid medication or hormone replacement therapy, dose been has been constant for at least 2 months prior to Screening Visit
* If taking vitamin C supplement \>60 mg/d, is willing to discontinue throughout the duration of the study
* Willing to take non-aspirin pain relievers through the duration of the study
* Voluntarily signed and dated an informed consent form (ICF), approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), and provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization prior to any participation in the study.

Exclusion Criteria

* Not taking oral anti-hyperglycemic medications (e.g., controlled by diet); is taking other oral anti-hyperglycemic medications other than metformin, thiazolidinones, or sulfonylureas; or on injectable medications (e.g., exenatide, insulin) for glucose control
* History of diabetic ketoacidosis
* History of metabolic/endocrine (other than diabetes), hepatic, or significant renal disease
* Follows a non-typical eating pattern, such as very low carbohydrate diet, strict vegetarianism
* Currently using diabetes-specific nutritional product(s), defined as more than one eating occasions per week
* Non-typical or erratic sleep-wake pattern, such as nightshift worker, chronic insomnia
* Pregnant as confirmed via urine pregnancy test, attempting to conceive or not willing and able to practice birth control during the study duration (only applicable to female subjects)
* Skin lesions, hyperhidrosis, eczema, psoriasis, scarring, tattoos, redness, infection or edema at the application sites that in the opinion of the study investigator or study physician could interfere with device placement or the accuracy of interstitial glucose measurements
* X-ray, MRI or CT appointment scheduled during the period of study participation, and the appointment cannot be rescheduled for a time before study participation starts or after study participation ends
* Current infection (requiring medication or which might be expected to require hospitalization); has had inpatient surgery, or corticosteroid treatment (excluding topical creams) in the last 3 months or antibiotics in the last 3 weeks prior to Screening Visit
* Active malignancy, excluding carcinoma in-situ of the cervix, cutaneous malignancies (basal cell carcinoma, squamous cell carcinoma, except melanoma)
* Chronic, contagious, infectious disease, such as active tuberculosis, Hepatitis A, B or C, or HIV
* History of bariatric surgery including gastric balloon; history of gastrointestinal disease (e.g., crohns, colitis, celiac) or intestinal surgery that can interfere with consumption/digestion/absorption of study product
* Habitually engages in strenuous exercise (e.g., high intensity aerobic exercise; including heavy physical labor), duration of 1 hour or longer, 3 or more times per week
* Known to be allergic or intolerant to any ingredient found in the study products
* Currently taking any medications, herbals, or dietary supplements, other than allowed medications, during the past 4 weeks that could profoundly affect (in the opinion of the PI or study physician) blood glucose or appetite
* Eating disorder, severe dementia or delirium, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures
* Participant in a concomitant AN trial or trial of a nonregistered drug (or is within the 30 day follow-up period for such a trial) or that otherwise conflicts with this study

Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes